左捆分支区域节奏:心脏再同步治疗的新时代?
Carlo Alberto Caruzzo1, Elia Rigamonti2, Francesca Romana Scopigni2
1Department of Cardiology, Istituto Cardiocentro del Ticino, Lugano 6900, TI, Switzerland. carloalberto.caruzzo@gmail.com.
World journal of cardiology
|October 1, 2024
概括
左捆支部区域节奏 (LBBAP) 是心脏再同步疗法 (CRT) 两心室节奏的可行的替代方案. 与传统方法相比,LBBAP显著改善了患者的治疗结果和心脏功能.
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
- 医疗器械 医疗器械
背景情况:
- 心脏再同步疗法 (CRT) 是心力衰竭的标准治疗方法.
- 传统的CRT经常使用双心脏节奏,这有局限性.
- 左捆分支区域节奏 (LBBAP) 是一种新兴的生理节奏技术.
研究的目的:
- 系统地审查和元分析LBBAP在接受CRT的患者中的可行性和有效性.
- 为了比较LBBAP与传统的双心脏节奏.
主要方法:
- 有关临床试验的系统审查和元分析.
- 对QRS持续时间,功能类,生物标志物,节奏值和心声共振参数的数据进行分析.
主要成果:
- LBBAP显示QRS持续时间和纽约心脏协会功能类的显著减少.
- 接受LBBAP治疗的患者显示B型尿素水平和节奏值降低.
- 与双心室节奏相比,使用LBBAP观察到心声学参数的改善.
结论:
- LBBAP是一种可行且有效的CRT生理节奏策略.
- 与双心室节奏相比,LBBAP提供了显著的临床和心声学益处.
- 在心力衰竭管理中,LBBAP代表了CRT的有希望的进步.
相关概念视频
Electrophysiology of Normal Cardiac Rhythm
2.3K
The normal cardiac rhythm is a synchronized electrical activity that facilitates the regular and coordinated contraction of the heart muscle. This process is essential for efficient blood circulation throughout the body. The fundamental elements involved in establishing and maintaining this rhythm include the unique electrical properties of cardiac muscle cells, the sinoatrial (SA) node's pacemaker function, the specialized conducting system, and the ionic mechanisms underlying each phase...
2.3K
Dysrhythmias VI: Management of Dysrhythmias
3
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
3
Cardiomyopathy II: Dilated Cardiomyopathy
1
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
1
Heart Failure Drugs: Inotropic Agents
535
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
535
Heart Failure VI: Adjunct Therapies
5
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
5
Cardiopulmonary Resuscitation III: AED Use
2
Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
2


